TUCSON, Ariz., July 16, 2019 /PRNewswire/ — UAVenture Capital Fund (UAVC), a Tucson based venture capital fund dedicated to the University of Arizona commercialization of discovery products, technology and services, today announced its seventh portfolio investment and the second investment from Fund II.
The Fund has invested in iCrx, Inc. a Wyant College of Optical Sciences technology that will introduce a compact automatic phoropter utilizing laser technology designed to instantly determine a required eyewear prescription. The phoropter is the common name for an ophthalmic testing device, also called a refractor, invented in 1921. It is still commonly used by eye care professionals during a prescription eye examination and contains different lenses used for refraction of the eye during sight testing. Such testing measures an individual’s refractive error and determines his or her eyeglass prescription.
The new iCrx invention is a hand-held device that can produce an objective and accurate eyeglass prescription in approximately 20 seconds without any subjective input from the viewer.
The invested funds from UAVC will be utilized to further develop and miniaturize the technology into a commercial product to be used in kiosks and/or in rapid screening of large patient populations especially in developing countries that lack sufficient facilities and specialist doctors.
Dr. Gholam Peyman, an ophthalmologist, retinal surgeon, and professor of both Clinical Ophthalmology and Basic Medical Sciences at the University of Arizona College of Medicine in Phoenix, Arizona invented the original iCrx technology. Dr. Peyman is also the Research Director for the Department of Ophthalmology and is best known for his invention of LASIK eye surgery. University of Arizona Wyant College of Optical Sciences faculty Dr. Nasser Peyghambarian and Dr. James Schweigerling, co-inventors of the technology, have been designing the compact phoropter prototype. Several students at the University of Arizona are also working on the project.
About UAVC:
UAVenture Capital Fund II, LLC is a Tucson based investment fund designed specifically to help finance University of Arizona connected enterprises including the commercialization of faculty led innovations originating at the University of Arizona. The fund provides early stage capital to companies where the science or service array was pioneered by faculty members, students and/or colleagues at the University of Arizona, one of the top research universities in the world.
About University of Arizona James C. Wyant College of Optical Sciences:
The University of Arizona College of Optical Sciences is one of the world’s premier educational and research institutions in optics and photonics. Its focus is on educating outstanding students with a broad foundation in all areas of optics and on providing practical experience while developing highly competitive technical skills. The research programs include optical engineering, fundamental optical physics, photonics, and image science. The College provides unique opportunities to pursue cutting-edge applications of optics in real-life systems. Graduates become professors, scientists, engineers and entrepreneurs, working in academia, industry, government and business around the globe.
View original content to download multimedia:http://www.prnewswire.com/news-releases/uaventure-capital-fund-invests-in-automatic-eyeglass-prescription-technology-300886183.html
SOURCE UAVenture Capital Fund, LLC
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI)…
D-bal-max D-Bal MAX Glasgow, June 15, 2025 (GLOBE NEWSWIRE) -- In the quest for enhanced…
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment…
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response…
After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients…
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were…